Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that it received approvals from the National Medical Products Administration of China for the production and registration of three new drugs: Urapidil Sustained-release Capsules, Nicardipine Hydrochloride and Sodium Chloride Injection, and Drotaverine Hydrochloride Injection. These approvals mark significant milestones as they are the first of such approvals for these types of drugs in China, potentially enhancing SSY Group’s market position and expanding its product offerings in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a company involved in the pharmaceutical industry, focusing on the development and production of chemical drugs. Their primary products include medications for hypertension and smooth muscle spasms, with a market focus on providing treatments for these conditions in China.
YTD Price Performance: -17.80%
Average Trading Volume: 13,270,514
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.38B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.